Seeking Alpha

A federal appeals court issues a mixed ruling for Myriad Genetics (MYGN -1%), reversing a lower...

A federal appeals court issues a mixed ruling for Myriad Genetics (MYGN -1%), reversing a lower court ruling which held that the drug developer's "isolated" DNA molecules aren't eligible for patents. However, the court also upholds the lower court's finding that MYGN's methods for comparing or analyzing DNA aren't eligible for patents. The company says it's still a win, as the gene patent claims were the meat of the case.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|